221 related articles for article (PubMed ID: 32154255)
1. Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes.
Vitale A; Cavalli G; Ruscitti P; Sota J; Colafrancesco S; Priori R; Valesini G; Argolini LM; Baldissera E; Bartoloni E; Cammelli D; Canestrari G; Cavallaro E; Massaro MG; Cipriani P; De Marchi G; De Vita S; Emmi G; Frassi M; Gerli R; Gremese E; Iannone F; Fornaro M; Paladini A; Lopalco G; Manna R; Mathieu A; Montecucco C; Mosca M; Piazza I; Piga M; Pontikaki I; Romano M; Rossi S; Rossini M; Silvestri E; Stagnaro C; Talarico R; Frediani B; Tincani A; Viapiana O; Vitiello G; Galozzi P; Sfriso P; Gaggiano C; Grosso S; Rigante D; Dagna L; Giacomelli R; Cantarini L
Front Med (Lausanne); 2020; 7():42. PubMed ID: 32154255
[No Abstract] [Full Text] [Related]
2. Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response.
Vitale A; Cavalli G; Colafrancesco S; Priori R; Valesini G; Argolini LM; Baldissera E; Bartoloni E; Cammelli D; Canestrari G; Sota J; Cavallaro E; Massaro MG; Ruscitti P; Cipriani P; De Marchi G; De Vita S; Emmi G; Ferraccioli G; Frassi M; Gerli R; Gremese E; Iannone F; Lapadula G; Lopalco G; Manna R; Mathieu A; Montecucco C; Mosca M; Piazza I; Piga M; Pontikaki I; Romano M; Rossi S; Rossini M; Silvestri E; Stagnaro C; Talarico R; Tincani A; Viapiana O; Vitiello G; Galozzi P; Sfriso P; Gaggiano C; Rigante D; Dagna L; Giacomelli R; Cantarini L
Front Pharmacol; 2019; 10():296. PubMed ID: 31001115
[No Abstract] [Full Text] [Related]
3. Anakinra for the treatment of adult-onset Still's disease.
Castañeda S; Atienza-Mateo B; Martín-Varillas JL; Serra López-Matencio JM; González-Gay MA
Expert Rev Clin Immunol; 2018 Dec; 14(12):979-992. PubMed ID: 30324816
[TBL] [Abstract][Full Text] [Related]
4. Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry.
Vitale A; Caggiano V; Maggio MC; Lopalco G; Emmi G; Sota J; La Torre F; Ruscitti P; Bartoloni E; Conti G; Fabiani C; Mattioli I; Gaggiano C; Cardinale F; Dagna L; Campochiaro C; Giacomelli R; Balistreri A; Laskari K; Tufan A; Ragab G; Almaghlouth IA; Więsik-Szewczyk E; Pereira RM; Frediani B; Iannone F; Sfikakis PP; Cantarini L
Front Med (Lausanne); 2022; 9():1071732. PubMed ID: 36619631
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Anakinra in Refractory Adult-Onset Still's Disease: Multicenter Study of 41 Patients and Literature Review.
Ortiz-Sanjuán F; Blanco R; Riancho-Zarrabeitia L; Castañeda S; Olivé A; Riveros A; Velloso-Feijoo ML; Narváez J; Jiménez-Moleón I; Maiz-Alonso O; Ordóñez C; Bernal JA; Hernández MV; Sifuentes-Giraldo WA; Gómez-Arango C; Galíndez-Agirregoikoa E; Blanco-Madrigal J; Ortiz-Santamaria V; Del Blanco-Barnusell J; De Dios JR; Moreno M; Fiter J; Riscos ML; Carreira P; Rodriguez-Valls MJ; González-Vela MC; Calvo-Río V; Loricera J; Palmou-Fontana N; Pina T; Llorca J; González-Gay MA
Medicine (Baltimore); 2015 Sep; 94(39):e1554. PubMed ID: 26426623
[TBL] [Abstract][Full Text] [Related]
6. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study.
Colafrancesco S; Priori R; Valesini G; Argolini L; Baldissera E; Bartoloni E; Cammelli D; Canestrari G; Cantarini L; Cavallaro E; Cavalli G; Cerrito L; Cipriani P; Dagna L; Marchi G; Vita S; Emmi G; Ferraccioli G; Frassi M; Galeazzi M; Gerli R; Giacomelli R; Gremese E; Iannone F; Lapadula G; Lopalco G; Manna R; Mathieu A; Montecucco C; Mosca M; Piazza I; Piga M; Pontikaki I; Romano M; Rossi S; Rossini M; Ruscitti P; Silvestri E; Stagnaro C; Talarico R; Tincani A; Viapiana O; Vitiello G; Fabris F; Bindoli S; Punzi L; Galozzi P; Sfriso P
Front Pharmacol; 2017; 8():369. PubMed ID: 28659802
[No Abstract] [Full Text] [Related]
7. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease.
Vitale A; Berlengiero V; Sota J; Ciarcia L; Ricco N; Barneschi S; Mourabi M; Lopalco G; Marzo C; Bellisai F; Iannone F; Frediani B; Cantarini L
Mediators Inflamm; 2020; 2020():8054961. PubMed ID: 33122969
[TBL] [Abstract][Full Text] [Related]
8. Application of systems biology-based in silico tools to optimize treatment strategy identification in Still's disease.
Segú-Vergés C; Coma M; Kessel C; Smeets S; Foell D; Aldea A
Arthritis Res Ther; 2021 Apr; 23(1):126. PubMed ID: 33892792
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France.
Lequerré T; Quartier P; Rosellini D; Alaoui F; De Bandt M; Mejjad O; Kone-Paut I; Michel M; Dernis E; Khellaf M; Limal N; Job-Deslandre C; Fautrel B; Le Loët X; Sibilia J; ;
Ann Rheum Dis; 2008 Mar; 67(3):302-8. PubMed ID: 17947302
[TBL] [Abstract][Full Text] [Related]
10. Diagnosing and Treating Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease as Part of the Still's Disease Continuum.
Kontzias A; Petryna O; Nakasato P; Efthimiou P
Mediterr J Rheumatol; 2024 Mar; 35(Suppl 1):45-57. PubMed ID: 38756937
[TBL] [Abstract][Full Text] [Related]
11. Management of adult-onset Still's disease with interleukin-1 inhibitors: evidence- and consensus-based statements by a panel of Italian experts.
Colafrancesco S; Manara M; Bortoluzzi A; Serban T; Bianchi G; Cantarini L; Ciccia F; Dagna L; Govoni M; Montecucco C; Priori R; Ravelli A; Sfriso P; Sinigaglia L;
Arthritis Res Ther; 2019 Dec; 21(1):275. PubMed ID: 31829244
[TBL] [Abstract][Full Text] [Related]
12. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review).
Junge G; Mason J; Feist E
Semin Arthritis Rheum; 2017 Oct; 47(2):295-302. PubMed ID: 28757235
[TBL] [Abstract][Full Text] [Related]
13. Macrophage activation syndrome complicating adult onset Still's disease: A single center case series and comparison with literature.
Lenert A; Yao Q
Semin Arthritis Rheum; 2016 Jun; 45(6):711-6. PubMed ID: 26672682
[TBL] [Abstract][Full Text] [Related]
14. Adult-onset Still's disease: Advances in the treatment.
Castañeda S; Blanco R; González-Gay MA
Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):222-238. PubMed ID: 27886796
[TBL] [Abstract][Full Text] [Related]
15. Rapid responses to anakinra in patients with refractory adult-onset Still's disease.
Fitzgerald AA; Leclercq SA; Yan A; Homik JE; Dinarello CA
Arthritis Rheum; 2005 Jun; 52(6):1794-803. PubMed ID: 15934079
[TBL] [Abstract][Full Text] [Related]
16. Anakinra in Still's disease: a profile of its use.
Lyseng-Williamson KA
Drugs Ther Perspect; 2018; 34(12):543-553. PubMed ID: 30546251
[TBL] [Abstract][Full Text] [Related]
17. A retrospective study of patients with adult-onset Still's disease: is pericarditis a possible predictor for biological disease-modifying anti-rheumatic drugs need?
Dall'Ara F; Frassi M; Tincani A; Airò P
Clin Rheumatol; 2016 Aug; 35(8):2117-2123. PubMed ID: 26758435
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity.
Kudela H; Drynda S; Lux A; Horneff G; Kekow J
BMC Rheumatol; 2019; 3():4. PubMed ID: 30886992
[TBL] [Abstract][Full Text] [Related]
19. Adult-onset Still's disease.
Gerfaud-Valentin M; Jamilloux Y; Iwaz J; Sève P
Autoimmun Rev; 2014 Jul; 13(7):708-22. PubMed ID: 24657513
[TBL] [Abstract][Full Text] [Related]
20. Drug retention rates of biological agents in adult onset Still's disease.
Campochiaro C; Farina N; Tomelleri A; De Luca G; Baldissera E; Cavalli G; Dagna L
Semin Arthritis Rheum; 2021 Feb; 51(1):1-6. PubMed ID: 33340821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
